|
KMID : 1039320170170010088
|
|
Journal of Liver Cancer
2017 Volume.17 No. 1 p.88 ~ p.93
|
|
|
A Case of Achieving Complete Remission with Combination of Sorafenib and Tegafur in Patients with Hepatocellular Carcinoma with Progression of Disease after Sorafenib Therapy
|
|
Hwang Sang-Youn
Lee Seon-Mi
Im Jung-Woo
Jeon Ki-Jeong
Ahn Sang-Bu
Park Jin-Young
Choi Chul-Won
Yang Gwang-Mo
|
|
|
Abstract
|
|
|
|
Sorafenib is the only approved targeted agent as the first line systemic therapy for treatment of advanced hepatocellular carcinoma (HCC). However, the improvement of survival duration under 3 months is far from clinical satisfactory and most patients experience disease progression within 6 months after sorafenib therapy. Unfortunately, second line systemic therapy after treatment failure of sorafenib was not established and there were no clear guidelines for salvage treatment modalities. Recently, studies suggests that combination of sorafenib and single cytotoxic agent can be relatively effective and safe strategy that achieves promising rates of local and systemic control in advanced HCC patients. Based on above suggestions, we herein offer our experience of a case achieved complete remission by combination therapy of sorafenib and tegafur in the patient with progressed disease after sorafenib therapy.
|
|
|
KEYWORD
|
|
|
Sorafenib, Hepatocellular carcinoma, Refractory, Cytotoxic agent, Combination
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|